TAKEDA PHARMACEUTICAL COMPANY LIMITED Takeda Pharmaceutical Company Limited Stock Börse Stuttgart
Equities
TKD
JP3463000004
Pharmaceuticals
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.72 EUR | -0.80% |
|
+3.75% | -3.49% |
| Sales 2024 | 4,264B 27.35B 25.14B | Sales 2025 * | 4,252B 27.27B 25.07B | Capitalization | 6,594B 42.3B 38.89B |
|---|---|---|---|---|---|
| Net income 2024 | 144B 924M 850M | Net income 2025 * | 116B 747M 687M | EV / Sales 2024 | 1.54 x |
| Net Debt 2024 * | 3,771B 24.19B 22.24B | Net Debt 2025 * | 4,224B 27.1B 24.91B | EV / Sales 2025 * | 2.54 x |
| P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
59.8
x | Employees | - |
| Yield 2024 |
4.49% | Yield 2025 * |
4.6% | Free-Float | 99.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Takeda Pharmaceutical Company Limited
More recommendations
More press releases
More news
| 1 week | +3.75% | ||
| Current month | +2.34% | ||
| 1 month | -2.12% | ||
| 3 months | -5.75% | ||
| 6 months | -3.52% | ||
| Current year | -3.49% |
1 week
23.93
24.92
1 month
23.6024.92
3 years
23.2431.72
5 years
23.2437.82
10 years
23.2450.30
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
| Date | Price | Change |
|---|---|---|
| 24-06-06 | 24.9 | -0.08% |
| 24-06-05 | 24.92 | +2.34% |
| 24-06-04 | 24.35 | -0.16% |
| 24-06-03 | 24.39 | +0.16% |
| 24-05-31 | 24.35 | +1.76% |
Delayed Quote Börse Stuttgart, June 06, 2024 at 02:22 am EDT
More quotes
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
2024-06-25
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,215
JPY
Average target price
4,790
JPY
Spread / Average Target
+13.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.24% | 749B | |
| +39.42% | 605B | |
| -6.64% | 351B | |
| +18.85% | 328B | |
| +7.90% | 292B | |
| +11.92% | 216B | |
| -2.62% | 214B | |
| +0.61% | 167B | |
| +6.92% | 165B |
- Stock Market
- Equities
- 4502 Stock
- TKD Stock
